Thermo Fisher Partners with Arcturus on Phase III Cystic Fibrosis Trial

Thermo Fisher Scientific (NYSE: TMO) announced a partnership with Arcturus Therapeutics to support the Phase III clinical trial of ARCT-032, an investigational mRNA therapy for cystic fibrosis. Under the agreement, Thermo Fisher will provide integrated manufacturing, clinical research, and commercial readiness services.

The Product

ARCT-032 is an mRNA-based therapy designed to treat cystic fibrosis, a genetic disorder affecting the lungs and digestive system. It aims to restore the function of the CFTR protein, which regulates ion transport.

Pricing and Availability

Pricing and launch timeline have not been disclosed and will depend on trial outcomes and regulatory approvals.

Competition

ARCT-032 competes with approved therapies such as Vertex Pharmaceuticals' Trikafta, the current standard of care, as well as other mRNA-based candidates in development.

Potential Impact on Thermo Fisher

This partnership strengthens Thermo Fisher's position as a leading contract development and manufacturing organization (CDMO) in the biopharma sector and opens opportunities in the multi-billion-dollar cystic fibrosis market.